Venoruton 500 mg - treatment of venous insufficiency & capillary fragility 30 coated tablets

Product Description

Active ingredients

Venoruton 1000 mg granules: One sachet contains – Active ingredient: oxerutine 1000 mg.
Venoruton 500 mg coated tablets: One tablet contains: Active ingredient: oxerutine 500 mg.
Excipients with known effect: sunset yellow (E 110) Venoruton 2% gel: 100 g of gel contain: Active ingredient: oxerutine 2 g. Excipients with known effect: benzalkonium chloride

Excipients

Venoruton 1000 mg granules: mannitol; sodium saccharin; citric acid monohydrate. Venoruton 500 mg coated tablets: 30% polyacrylate dispersion; talc; magnesium stearate; macrogols; copovidone; sunset yellow (E 110); titanium dioxide. Venoruton 2% gel for cutaneous use: carbomers; sodium hydroxide; disodium edetate; benzalkonium chloride; purified water.

Therapeutic indications

VENORUTON is indicated in the treatment of symptoms related to venous insufficiency; capillary fragility states.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.

Dosage

Venoruton 1000 mg granules: 2 to 3 sachets per day, depending on the severity of the symptom. The contents of each sachet of granules should be carefully dissolved in a little water and taken before or during meals, even in cases of venous insufficiency of the hemorrhoidal plexus. Venoruton 500 mg coated tablets: 2–3 tablets per day. The tablets should be swallowed whole with a little water, without chewing, before or during meals, even in cases of venous insufficiency of the hemorrhoidal plexus. Venoruton 2% gel for cutaneous use: apply an adequate amount of gel to the affected area and surrounding areas, twice a day (morning and evening). Massage lightly to allow the medicine to penetrate until completely absorbed, that is, until the skin feels dry when touched. Do not exceed the recommended dose. The success of treatment depends largely on the regular administration of a sufficiently high dose for a prolonged period of treatment.

Warnings and precautions

Venoruton gel: Use, especially if prolonged, of products to be applied to the skin may give rise to sensitization phenomena. In this case, treatment should be discontinued and your doctor should be consulted to establish appropriate therapy. Important information about some of the excipients Venoruton 500 mg film-coated tablets contain sunset yellow (E 110), which may cause allergic reactions. Venoruton gel contains benzalkonium chloride, which is an irritant. It may cause local skin reactions.

Interactions

None known to date.

Side effects

Venoruton is well tolerated, as widely documented in the vast international literature. Even when treatment was continued for several months, no noteworthy side effects were ever reported. Mild digestive disturbances were rarely observed with Venoruton 1000 mg granules, which disappeared upon discontinuation of treatment. Only rare cases of sensitization with the appearance of skin reactions were observed with Venoruton gel. These symptoms rapidly regress upon discontinuation of treatment.

Pregnancy and breastfeeding

The safety of the drug during pregnancy has not been established; therefore, it is advisable not to administer the product during pregnancy. There are no preclusions to the use of the preparation during breastfeeding.